Epimed International, Inc
$506.9K 33 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Roche Diabetes Care, Inc.
Roche Diabetes Care, Inc. reported $505,278.07 across General Payments, Research, and Ownership to 18 physicians and teaching hospitals across 60 transactions.
- $505.3K Above-median payer
- All-tracks total
- 60 Below-median volume
- Transactions
- 18 Below-median reach
- Recipients
- +$2.9K
- General Payments vs PY2023
Roche Diabetes Care, Inc. reported $505,278.07 across all CMS Open Payments tracks (General + Research + Ownership) to 18 physicians and teaching hospitals in Program Year 2024 - ranking #760 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $9,064.34, averaging $28.1K per recipient.
How Roche Diabetes Care, Inc.'s $505.3K all-tracks total breaks down
Roche Diabetes Care, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
15/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer roche-diabetes-care-inc Roche Diabetes Care, Inc.
$505.3K · #760/1,925 · 0.0% industry · PY2024
- TOT $505.3K
- RANK #760
- SHARE 0.0%
- TXN 60
- RCP 18
- CAT 2
- GEN $9.1K
- ΔGEN +$2.9K
- TOP1 8.6%
- PY 2024
Volume peers
Nearest volume peer: Epimed International, Inc ($506.9K)
Roche Diabetes Care, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Roche Diabetes Care, Inc.'s CMS-reported General Payments increased by $2.9K (+46.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ROCHE DIABETES CARE, INC.PY2023: ROCHE DIABETES CARE, INC.PY2024: ROCHE DIABETES CARE, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,202.39
- PY2024
- $9,064.34
What the Data Shows for Roche Diabetes Care, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Roche Diabetes Care, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $8.7K, accounting for 95.5% of this company's General Payments and 15 transactions.
General Payment Breakdown by Type
Across 2 types of general payments, Roche Diabetes Care, Inc.'s largest category was "Consulting Fee" at $8.7K - 95.5% of General Payments.
How Roche Diabetes Care, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $8.7K | 15 | 95.5% |
| Food and Beverage | $404.34 | 3 | 4.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,885.00 (42.9%) of $9,064.34 in this company's General Payments records across 18 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Roche Diabetes Care, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Yevgeniy Kantor
$777.00 across 1 reported transactions
- 2
Melissa Katz
$777.00 across 1 reported transactions
- 3
Alina Gouller
$777.00 across 1 reported transactions
- 4
Chithranjan Nath
$777.00 across 1 reported transactions
- 5
Alan Dresner
$777.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Roche Diabetes Care, Inc. ranks #760 of 1,925 by total payments (top 39% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,185 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
- Swedish Orphan Biovitrum Ab : $276.4K total payments, HHI 679
- Stereotaxis Inc : $15.7K total payments, HHI 679
- TheracosBio, LLC : $7.4K total payments, HHI 674
- Keystone Dental Inc. : $492.7K total payments, HHI 673
- Roche Diabetes Care, Inc. (this company) : $9.1K total payments, HHI 672
- EvoEndo, Inc : $57.2K total payments, HHI 667
- Nexus Medical Technologies Llc : $4.1K total payments, HHI 667
- Sonex Health, Inc. : $428.3K total payments, HHI 666
- Xtant Medical Inc : $659.3K total payments, HHI 666
- Acella Pharmaceuticals, LLC : $103.8K total payments, HHI 660
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Roche Diabetes Care, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Roche Diabetes Care, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Roche Diabetes Care, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Central Indiana URS Consumables, LLC
$507.6K 14 recipients
Compare payment profiles
International Rehabilitative Sciences, Inc
$502.5K 1,661 recipients
Compare payment profiles
Insight Medical Systems, Inc.
$500.6K 237 recipients
Compare payment profiles
Thea Pharma Inc.
$512.0K 3,562 recipients
Compare payment profiles
Novartis Pharma AG
$513.5K 73 recipients
Compare payment profiles
Put this to use
Roche Diabetes Care, Inc. ranks #760 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Roche Diabetes Care, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.